UNSPSC 51292919: Dibenzepin hydrochloride

This classification denotes the hydrochloride form of a dibenzazepine and tricyclic antidepressive agent with the molecular formula C18H21N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 510SJZ1Y6L, chemically known as 5,10-dihydro-10-(2-(dimethylamino)ethyl)-5-methyl-11h-dibenzo(b,e)(1,4)diazepin-11-one but more generally known as dibenzepin, which bears US NIH Compound Identifier 9419. European Medicines Agency schedules Dibenzepin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07074MIG.

UNSPSC 51292919 Dibenzepin hydrochloride is a Commodity code that captures pharmaceutical products state and local governments procure for health and human services delivery, though recent solicitation activity under this specific code shows minimal direct alignment with dibenzepin itself. Instead, state and local health agencies are actively procuring broader pharmaceutical categories including naloxone, generic multi-source drugs, and over-the-counter products through competitive and cooperative purchasing mechanisms. The solicitations reveal procurement by county health authorities, state health and human services commissions, and regional multistate cooperative purchasing alliances that bundle pharmaceutical procurement across multiple jurisdictions and authorized wholesale channels. Work under the code reflects a shift toward direct-to-manufacturer relationships and cost-containment strategies, with vendors managing quarterly or annual delivery cycles to public health facilities and supporting statewide pharmacy benefit programs.

Recent activity appears concentrated in Florida and Minnesota, with Texas health agencies conducting exploratory procurement for prescription programs. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2026, requiring quarterly deliveries to the Seminole County Community Health Building in Sanford and vendor-managed shipping costs. The Minnesota Department of Administration's MMCAP issued RFP S1070000015802 on January 20, 2026 with a March 26, 2026 response deadline to establish multi-award contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), with evaluations weighted 75 percent on price competitiveness and effective dates of July 1, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to explore vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, seeking information on direct contracting capacity and value-based agreements outside traditional pharmacy benefit manager and group purchasing organization channels.